[go: up one dir, main page]

AR054129A1 - Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 - Google Patents

Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7

Info

Publication number
AR054129A1
AR054129A1 ARP060102077A ARP060102077A AR054129A1 AR 054129 A1 AR054129 A1 AR 054129A1 AR P060102077 A ARP060102077 A AR P060102077A AR P060102077 A ARP060102077 A AR P060102077A AR 054129 A1 AR054129 A1 AR 054129A1
Authority
AR
Argentina
Prior art keywords
alfa4beta7
treatment
medicines
quinolinilo
alfa4beta1
Prior art date
Application number
ARP060102077A
Other languages
English (en)
Inventor
B Perry
Original Assignee
Uc S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511781A external-priority patent/GB0511781D0/en
Priority claimed from GB0600213A external-priority patent/GB0600213D0/en
Application filed by Uc S A filed Critical Uc S A
Publication of AR054129A1 publication Critical patent/AR054129A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composicion farmacéutica que los contiene y su uso para preparar medicamentos para el tratamiento de enfermedades mediadas por alfa4beta1 y/o alfa4beta7. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), sus enantiomeros, diastereoisomeros o una sal de éstos aceptables desde el punto de vista farmacéutico, donde: R1 es hidrogeno, hidroxilo o alquilo C1-6; R2 es hidrogeno o halogeno; n es de 0 a 5; R3 es hidrogeno, o halogeno; n' es de 0 a 4.
ARP060102077A 2005-06-09 2006-05-22 Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 AR054129A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0511781A GB0511781D0 (en) 2005-06-09 2005-06-09 2,6-quinolinyl derivatives, processes for preparing them and their uses
US20615805A 2005-08-18 2005-08-18
GB0600213A GB0600213D0 (en) 2006-01-06 2006-01-06 2,6-quinolinyl derivatives, processes for preparing them and their uses

Publications (1)

Publication Number Publication Date
AR054129A1 true AR054129A1 (es) 2007-06-06

Family

ID=36968449

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102077A AR054129A1 (es) 2005-06-09 2006-05-22 Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7

Country Status (19)

Country Link
US (1) US7732614B2 (es)
EP (1) EP1902045B1 (es)
JP (1) JP2008542407A (es)
KR (1) KR20080021085A (es)
AR (1) AR054129A1 (es)
AT (1) ATE496041T1 (es)
AU (1) AU2006254772B2 (es)
BR (1) BRPI0611243A2 (es)
CA (1) CA2610800A1 (es)
DE (1) DE602006019731D1 (es)
EA (1) EA013080B1 (es)
IL (1) IL187235A0 (es)
MX (1) MX2007014721A (es)
MY (1) MY140739A (es)
NO (1) NO20080125L (es)
NZ (1) NZ563739A (es)
PE (1) PE20070081A1 (es)
TW (1) TW200716605A (es)
WO (1) WO2006131200A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04010673A (es) 2002-04-30 2005-09-30 Ucb Sa Derivados de 2,6-quinolinilo y 2,6-naftilo, procesos para su preparacion y sus usos como inhibidores de la vla-4.
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP2808033A1 (en) * 2004-11-19 2014-12-03 Biogen Idec MA Inc. Treatment for multiple sclerosis
ATE496041T1 (de) 2005-06-09 2011-02-15 Ucb Pharma Sa 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel
WO2008125215A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
MX2011010971A (es) * 2009-04-17 2012-01-19 Biogen Idec Inc Composiciones y metodos para tratar leucemia mielogena aguda.
SI2558499T1 (sl) 2010-04-16 2017-08-31 Biogen MA Inc., Protitelesa proti VLA-4
MY160723A (en) * 2013-12-30 2017-03-15 Univ Putra Malaysia An anticoagulant
USD812958S1 (en) 2016-06-08 2018-03-20 Samsung Electronics Co., Ltd. Cooktop
TWI856956B (zh) 2018-04-12 2024-10-01 美商莫菲克醫療股份有限公司 人類整合素α４β７拮抗劑
KR20210027352A (ko) 2018-06-04 2021-03-10 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
JP7189368B2 (ja) * 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
WO2021076902A1 (en) 2019-10-16 2021-04-22 Morphic Therapeutic, Inc. INHIBITING HUMAN INTEGRIN α 4 β 7

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018606A1 (fr) 1994-12-14 1996-06-20 Santen Pharmaceutical Co., Ltd. Nouveaux derives 1,3-dialkyluree
PL193283B1 (pl) 1997-08-22 2007-01-31 Hoffmann La Roche Nowe pochodne N-aroilofenyloalaniny, ich zastosowanie i środek leczniczy
AU754557B2 (en) 1998-08-26 2002-11-21 Aventis Pharma Limited Aza-bicycles which modulate the inhibition of cell adhesion
BR0010139A (pt) 1999-04-28 2004-03-02 Reddy Research Foundation Heterociclos bicìclicos substituìdos, processo para seu preparo e seu uso como agentes anti-obesidade e hipocolesterolêmico
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
MXPA04010673A (es) * 2002-04-30 2005-09-30 Ucb Sa Derivados de 2,6-quinolinilo y 2,6-naftilo, procesos para su preparacion y sus usos como inhibidores de la vla-4.
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0329584D0 (en) 2003-12-20 2004-01-28 Tanabe Seiyaku Co Novel compounds
ATE496041T1 (de) 2005-06-09 2011-02-15 Ucb Pharma Sa 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
AU2006254772B2 (en) 2011-06-02
MY140739A (en) 2010-01-15
CA2610800A1 (en) 2006-12-14
KR20080021085A (ko) 2008-03-06
AU2006254772A1 (en) 2006-12-14
WO2006131200A1 (en) 2006-12-14
PE20070081A1 (es) 2007-02-15
BRPI0611243A2 (pt) 2010-08-24
EA200702589A1 (ru) 2008-06-30
US7732614B2 (en) 2010-06-08
NO20080125L (no) 2008-01-08
EP1902045B1 (en) 2011-01-19
MX2007014721A (es) 2008-02-14
US20070004775A1 (en) 2007-01-04
NZ563739A (en) 2009-12-24
EA013080B1 (ru) 2010-02-26
TW200716605A (en) 2007-05-01
EP1902045A1 (en) 2008-03-26
ATE496041T1 (de) 2011-02-15
JP2008542407A (ja) 2008-11-27
DE602006019731D1 (de) 2011-03-03
IL187235A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
AR055060A1 (es) Derivados de n-(piridin-2-il)-sulfonamida
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
AR071187A1 (es) Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
UY28578A1 (es) Derivados de amida
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
UY29927A1 (es) Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
UY30408A1 (es) Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
CL2011001413A1 (es) Compuestos derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para la prevencion o el tratamiento de una infeccion bacteriana.
UY29301A1 (es) Derivados amida
AR078722A1 (es) Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal